Aclaris Therapeutics up on enrollment completion in RA treatment trial

Aclaris Therapeutics

13/06/2023 17:01

** Drug developer Aclaris Therapeutics Inc's shares  ACRS.O 
up 5.2% at $9.71
    ** Co completes enrollment in mid-stage trial for its
experimental drug zunsemetinib, in treating patients with
moderate to severe rheumatoid arthritis (RA)
    ** RA is a chronic inflammatory disorder that affects the
joints and other body systems
    ** The dose-ranging study is testing two doses of the oral
drug candidate with the medicine methotrexate (MTX), vs placebo
plus MTX
    ** Top-line efficacy, safety and other preliminary data from
the trial expected in Q4 of 2023  
    ** Brokerage BTIG sees zunsemetinib as the largest source 
of near-term upside potential for ACRS shares, reiterates "buy"
rating on stock 
    ** In early March, the drug candidate had failed to meet the
main goal of a mid-stage study to treat a type of skin disorder
that causes skin abscesses and scarring
    ** Including session's gain, stock lost 38.4% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))